Age-adjusted prostate cancer-specific comorbidity index is strongly predictive of other-cause mortality, according to recent study data.
In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.
Association between smoking and development of various forms of cancer well established; however, evidence of prostate cancer link contradictory.
Prostate cancer diagnoses in the United States dropped 28% in year following USPSTF draft recommendation.
Adopting or retaining a Western-style diet after a prostate cancer diagnosis does little to improve cancer-related mortality or overall mortality, when compared to a healthier diet.
Men with advanced prostate cancer who possess AR-V7 respond just as well to chemotherapy as those who lack AR-V7.
Emotionally distressed men diagnosed with prostate cancer may be more likely to opt for surgery.
Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detection
A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.
Hospitals may invest in expensive, robot-assisted surgical models for performing radical prostatectomies (RARPs), but patients may benefit more from an experienced surgeon performing traditional open surgery.
Depending on the type of cancer faced, the needs of survivors can vary.
Men who are receiving androgen deprivation therapy (ADT) have an increased chance of experiencing impaired cognitive function.
When is chemotherapy or radium 223 the optimal treatment for men with advanced prostate cancer?
Researchers are examining what factors might make patients with prostate cancer more likely to experience hot flashes during and after therapy.
Men with prostate cancer that has spread to nearby lymph nodes may find the addition of radiation therapy to treatments that block the effects of testosterone beneficial.
Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.
Combination of docetaxel and hormone therapy can extend life by almost a year for prostate cancer patients, according to new research.
Rises in unemployment are associated with increases in deaths due to prostate cancer.
[Clinical Medicine Insights] In this case study, a 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene.
Men treated with androgen deprivation therapy (ADT) for prostate cancer more likely to demonstrate impaired cognitive performance.
The use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer doubled the chances of those individuals to be cancer-free 5 years later.
Addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer.
Statin use may slow prostate cancer progression in patients receiving androgen deprivation therapy, but more trials are needed to confirm benefits, researchers say.
Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT).
Treating gum disease reduced symptoms of prostate inflammation.
Postsurgical radiation therapy for prostate cancer at risk of recurrence is declining in the United States, despite evidence that it can be helpful.
For men with nonmetastatic castration resistant prostate cancer with a negative bone scan after diagnosis, factors associated with a second bone scan include higher PSA, shorter PSA doubling time, and faster PSA velocity; but under- and over-imaging may also be a factor.
An inexpensive, quick-result test has been shown in recently published studies to be more sensitive and more exacting than the current standard test for early stage prostate cancer.
Men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later.
Implementation of video-based decision aids for men lowered rates of elective surgery for benign prostatic hyperplasia (BPH) and decreased rates of active treatment for localized prostate cancer.
Two studies do not show protective effect of delayed radiation compared to earlier radiation for prostate cancer.
Post-diagnostic aspirin use is not associated with a decreased risk of prostate cancer outcomes, according to study data.
Resistance, aerobic exercise improves quality of life in older long-term survivors of prostate cancer
Aerobic and resistance exercise appears to have beneficial effects on health-related quality of life (HRQoL).
A higher fitness level leads to decreased risk of lung and colorectal cancer for men.
Truly shared decision-making is possible only when the patient understands everything the treatment options entail, and the doctor understands the patient's personal situation and desires.
After prostate cancer diagnosis, at least five hours of non-vigorous activity or 3 hours of walking is beneficial.
Bruce W. Hollis, PhD, discusses the findings from his study on the benefits of increasing vitamin D intake in patients with prostate cancer undergoing active surveillance.
Use of single dose of fluoroquinoloneis optimal prophylaxis to reduce infectious complications in patients undergoing prostate biopsy.
Aspirin use does not decrease the risk of mortality associated with prostate cancer.
Investigators sought to determine the incidence of injection site reactions (ISRs) after administration of degarelix.
New findings from researchers in Australia indicate dietary measures may prevent metastasis of prostate cancer.
An association of high rates of inappropriate imaging for prostate cancer and breast cancer found in a study of Medicare beneficiaries suggests that regional culture could contribute to inappropriate imaging.
Current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.
Study findings suggest that androgen receptor V7 (AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer.
An analysis of data on 945 patients with prostate cancer followed with active surveillance displayed outcome differences, depending on whether the patient was low- or intermediate-risk at diagnosis.
A mechanism in omega-3 fatty acids may inhibit the growth and spread of prostate cancer cells.
A family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer, according to a new study.
Novel nanotechnology could help men with prostate cancer make better decisions in treatment options.
Findings among men taking a statin alongside androgen deprivation therapy showed additional months of progression-free survival.
Regional infrastructure could contribute to inappropriate imaging in patients at risk for prostate and breast cancer.
Neither circulating 25-hydroxyvitamin D (25[OH]D) levels nor common variations in vitamin D pathway genes appear to be associated with risk of fatal prostate cancer, according to recent research.
A retrospective analysis of patient data found the proportion of men with diagnoses of intermediate- and high-risk prostate cancer increased by nearly 6% between 2011 and 2013.
Women with a family history of prostate cancer in first-degree relatives may have a higher risk of developing breast cancer.
Researchers report 3 percent annual rise in intermediate- and high-risk cases
The pioneering prostate cancer drug abiraterone can significantly extend the lives of men with advanced prostate cancer if administered prior to administering chemotherapy, according to phase III clinical trial data.
New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.
A recent study has determined that radiation therapy is the most common treatment for prostate cancer regardless of cancer stage, PSA level, or prognosis and risk rating.
Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.
Black men are less willing to be investigated for prostate cancer, thereby increasing the likelihood of being diagnosed.
When active surveillance is chosen, survival for intermediate-risk disease may be decreased.
Individuals who've had testicular cancer may be at increased risk for prostate cancer, but the overall risk is low, according to a study.
Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.
Variation was observed at a high-volume center when surgeons selected patients with low-risk prostate cancer to undergo radical prostatectomy, according to a study.
Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.
From 2004 to 2009, marked increase in observation among men with low-risk prostate cancer has been observed.
Guideline outlines recommended follow-up care for prostate cancer survivors
Smoking is associated with an increased risk of breast cancer, prostate cancer, and routine infections.
Targeted magnetic resonance (MR)/ultrasound fusion biopsy outperformed standard biopsy technique for increased detection of high-risk prostate cancer, according to a recent study.
Researchers identified certain factors associated with emotional distress in men with newly diagnosed prostate cancer.
Abiraterone significantly extends survival in men with advanced prostate cancer (PCa) if administered before chemotherapy.
Researchers have identified two genes that appear to be simultaneously overexpressed in aggressive prostate cancers resistant to the androgen-targeted treatments enzalutamide and abiraterone acetate.
Phosphodiesterase type 5 inhibitors up the risk of biochemical recurrence after radical prostatectomy, according to a recent study.
Prostate biopsies that combine both magnetic resonance imaging (MRI) technology and ultrasound appear to give more accurate results, according to a new study.
Former, as well as current, smokers saw higher risk for disease recurrence and radiation therapy-related urinary side effects.
Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.
Recent study confirmed the effects on smoking on patients with prostate cancer.
Examining more distant relations for prostate cancer can provide important patient history.
Study examines vaccine therapy in prostate cancer with rising prostate-specific antigen (PSA) levels
A vaccine therapy designed to boost the body's immune response may join available early treatment options for prostate cancer.
Focusing screening efforts on those with a positive family history of prostate cancer could be more effective.
The addition of radiation treatment to hormone therapy reduced more cancer deaths among older men locally advanced prostate cancer, compared to hormone therapy alone.
How men perceive their role within their family dynamic or social circles may impact how they respond to a cancer diagnosis. Often they retreat or shut down, further challenging the efforts of their oncology care providers and loved ones to help them cope.
A man's second-, third-degree relatives may be as significant as looking at his first-degree relatives to determine risk for developing prostate cancer.
Green tea may have a role a in the prevention and treatment of prostate cancer and other prostate conditions like prostatitis.
More than half of prostate cancer patients age 66 years and older have life expectancies of less than 10 years, yet half of them were over-treated for their prostate cancer with surgery, radiation, or brachytherapy.
This study investigated the effect of physical activity after a prostate cancer diagnosis on both overall and prostate cancer-specific mortality in a large cohort.
Current evidence seems to indicated that withholding T therapy in hypogonadal men cannot be justified.
Although prostate cancer can be successfully treated in many men, if the disease metastasizes to the bone, it is eventually lethal.
A recent meta-analysis demonstrated an association between aspirin and a reduced risk of prostate cancer.
The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).
Men receiving hormone therapy for prostate cancer may be missing out on protective meds, researchers say.
A new anticancer drug, already in clinical development, may help spare healthy cells from the effects of radiation treatments.
A genetic test has been developed to identify which men are at higher risk for prostate cancer recurrence after localized treatment with surgery or radiotherapy.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Prostate cancer patients with hereditary mutations in the BRCA genes do not respond as well to conventional treatment such as surgery and radiotherapy, and they have a lower survival rate than patients who do not have these genetic mutations.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
A new technique that employs advanced MRI scans to diagnose prostate cancer is being tested in a nationwide trial.
Metformin use associated with decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
Less than 20 percent of top-ranked health sites advise against screening for prostate cancer, a recommendation made by the USPSTF.
Active surveillance allows men with prostate cancer to delay or avoid the side effects of its treatment as well.
- Growing up with cancer: Understanding the challenges to adolescents and young adults (AYAs) coping with cancer
- Navigators have a key role in using genetics and genomics for cancer risk identification
- Using the navigation process to improve both your program and your patient outcomes
- Pilot program coordinates palliative care and support for rural communities
- Composing a CoC-compliant community health needs assessment (CHNA)
- Survivorship care plans: The shift back to primary care
- Scientists identify key to preventing metastatic breast cancer
- Noninvasive colon cancer screening promising for African Americans
- Cancer and intimate partner violence: Could you tell if one of your patients is a victim?
- Blood test detects breast cancer metastasis early
- Comorbid conditions associated with worse lung cancer survival
- Benefits found for screening colonoscopies of higher quality
- High-grade cervical lesions declining in young women
- Early relapse of follicular lymphoma may increase risk of death
- Study identifies perception gap in incidence, impact of CINV/RINV
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|